Clinical Trials (PDQ®)
|Phase III||Treatment||Closed||8 and under||NCI, Other||ANBL00P3|
NCI-2009-00399, CDR0000069271, COG-ANBL00P3, U10CA013539, U10CA098543, NCT00033293
This randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements associated with neuroblastoma. Drugs used in chemotherapy, work in different ways to stop tumor cells from dividing so they stop growing or die. Steroid therapy decreases inflammation. Combining chemotherapy and steroid therapy with immunoglobulin may be effective in treating abnormal muscle movement associated with neuroblastoma. Chemotherapy(cyclophosphamide), prednisone and intravenous gamma globulin all suppress the immune system which may be helpful in treating opsoclonus-myoclonus-ataxia (OMA).
Further Study Information
I. Determine if immunosuppressive therapy with cyclophosphamide and prednisone is an effective therapy for neuroblastoma associated opsoclonus-myoclonus-ataxia (OMA) and can constitute a back-bone therapy upon which to build additional therapy.
II. Determine in a randomized study if the addition of intravenous gammaglobulin therapy to the back-bone therapy of prednisone and cyclophosphamide improves response of neuroblastoma associated OMA.
I. Determine if intravenous gammaglobulin therapy improves the motor coordination of children diagnosed with neuroblastoma and presenting with OMA syndrome as assessed by neurological examination and the Vineland Adaptive Behavior Scale (VABS).
II. Determine these regimens improve functional outcome in these patients. III. Investigate the biology of neuroblastoma associated OMA, with specific regard to magnetic resonance imaging (MRI) findings, anti-neuronal antibodies, cerebrospinal fluid (CSF) findings and tumor biology.
IV. Define better the long-term prognosis for neurologic recovery in the child with neuroblastoma associated with OMA syndrome.
V. Define the event-free and overall survival of patients with neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome.
CHEMOTHERAPY: Patients with intermediate-risk or high-risk neuroblastoma receive chemotherapy (including cyclophosphamide) according to the standard of care for the stage of primary neuroblastoma, beginning on day 0. Patients with low-risk neuroblastoma (and not receiving other chemotherapy) receive cyclophosphamide IV over 1 hour on day 0. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. All patients receive oral prednisone twice daily for 3 months and then every other day for 7-15 months.
IMMUNE GLOBULIN THERAPY: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive immune globulin IV on days -2 and -1, at weeks 4, 8, 12, 16, 20, and 24, and then at months 8, 10, and 12 after therapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with no response after 6 months go off treatment.
ARM II: Patients do not receive immune globulin. Patients with unresponsive opsoclonus-myoclonus-ataxia syndrome after 2 months or progression after 6 months may cross over to arm I.
Patients are followed during therapy every month for 6 months, at 1 year, and then annually for up to 10 years.
- Newly diagnosed neuroblastoma (NBL) or ganglioneuroblastoma with tumor-associated opsoclonus-myoclonus-ataxia syndrome (OMA)
- Patients with NBL diagnosed within 6 months of OMA diagnosis AND patients with OMA diagnosed within 6 months of NBL diagnosis are eligible
- Must enroll on study within 4 weeks of diagnosis
- Presence of opsoclonus, myoclonus, and/or ataxia associated with neuroblastoma considered eligible
- Currently enrolled on COG neuroblastoma protocols: COG-ANBL00B1 or its successor
- No prior IV gamma globulin therapy
- No prior chemotherapy
- Concurrent chemotherapy allowed
- No prior prednisone or corticotropin
- Patients who have received ≤ 14 days of steroids are eligible
- Concurrent surgery allowed
- Patients must be free of any organ dysfunction or disorder that the treating physician feels may preclude the use of corticosteroid therapy (ACTH or prednisone), cyclophosphamide therapy or intravenous gammaglobulin therapy.
Trial Lead Organizations/Sponsors
Children's Oncology GroupNational Cancer Institute
|Pedro De Alarcon, MD||Principal Investigator|
|UAB Comprehensive Cancer Center|
|Alyssa T Reddy||Ph: 205-934-0309|
|Jonathan Jaques Children's Cancer Center at Miller Children's Hospital|
|Amanda M Termuhlen||Ph: 562-933-5437|
|Presbyterian - St. Luke's Medical Center|
|Jennifer J Clark||Ph: 866-775-6246|
|University of Kentucky Chandler Medical Center|
|Martha F Greenwood||Ph: 859-257-3379|
|Steven L Halpern||Ph: 973-971-5900|
|Legacy Emanuel Hospital and Health Center and Children's Hospital|
|Janice F Olson||Ph: 503-413-2560|
|Cancer Centers of the Carolinas - Faris Road|
|Cary E Stroud||Ph: 864-241-6251|
|Midwest Children's Cancer Center at Children's Hospital of Wisconsin|
|Michael E Kelly||Ph: 414-805-4380|
|Saskatoon Cancer Centre at the University of Saskatchewan|
|Christopher Mpofu||Ph: 306-655-2914|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00033293
ClinicalTrials.gov processed this data on January 29, 2015
Back to Top